Status:

RECRUITING

Turkish Version of the Hammersmith Neonatal Neurological Examination (HNNE)

Lead Sponsor:

Kahramanmaras Sutcu Imam University

Collaborating Sponsors:

Gazi University

Conditions:

Cerebral Palsy (CP)

Infant ALL

Eligibility:

All Genders

37-42 years

Brief Summary

High-risk infants are defined as an infant with a history of adverse environmental and biological factors that may lead to neuromotor developmental problems. This group includes premature babies born ...

Eligibility Criteria

Inclusion

  • Infants with periventricular hemorrhage, intracranial hemorrhage grades 2, 3, or 4, cystic periventricular leukomalacia (PVL), stage 3 hypoxic ischemic encephalopathy, neonatal bilirubin encephalopathy (kernicterus), perinatal stroke, perinatal asphyxia, and hydrocephalus.
  • Infants with chronic lung disease, respiratory lung disease (RDS), bronchopulmonary dysplasia (BPD), and long-term oxygen supplementation.
  • Preterm infants with sepsis due to gram-negative bacteria, necrotizing enterocolitis (NEC), and infantile apnea.
  • Preterm infants with a low 5-minute Apgar score (3 or below), diagnosed with intrauterine growth restriction, multiple births (twins, triplets), and preterm infants with Retinopathy of Prematurity (ROP).
  • Infants with prolonged severe hypoglycemia and hypocalcemia.
  • Babies who are small for gestational age (SGA), less than the 3rd percentile, or large for gestational age (LGA), greater than the 97th percentile.
  • Babies receiving mechanical ventilation for more than 24 hours.
  • Babies born at less than 32 weeks' gestation and weighing less than 1500 grams.

Exclusion

  • Babies with congenital malformations (spina bifida, congenital muscular torticollis, arthrogryposis multiplex congenita, etc.)
  • Babies diagnosed with metabolic and genetic diseases (Down syndrome, spinal muscular atrophy, Duchenne muscular dystrophy, etc.)
  • Babies still intubated and mechanically ventilated at 3 months postterm

Key Trial Info

Start Date :

August 22 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

March 15 2026

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT07182513

Start Date

August 22 2025

End Date

March 15 2026

Last Update

September 19 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Kahramanmaraş Sütçü imam University

Kahramanmaraş, Onikişubat, Turkey (Türkiye), 46100